Spain announces 250M HIPRA covid vaccines to be sold in European contract

Spain HIPRA covid vaccine European contract

Spain announces 250M HIPRA covid vaccines to be sold in European contract davide bonaldo/

The Prime Minister of Spain has announced that 250 million HIPRA covid vaccines are set to be sold in a new European contract, as reported on Tuesday, August 2.

Speaking on the Spain’s new European contract for 250 million vials of the HIPRA covid vaccine, Prime Minister Pedro Sanchez stated:

“This is very good news. It is a contract that demonstrates the strength of innovation and the pharmaceutical industry in our country, and also the public-private collaboration that we have developed with this Catalan and Spanish industry, which has borne fruit.”

Credit: Twitter @el_pais

A total of 14 European Member States will reportedly participate in this joint purchase, the value of which has not been reported by Brussels.

Under this agreement, 250 million vials of the HIPRA covid vaccine will be supplied as a booster dose for previously vaccinated people over the age of 16.

Among the adverse effects seen in the trials, the director of HIPRA reported “pain at the injection site, headache, some tiredness and, in fewer people, some discomfort that subsides after two or three days”.

The specialist believes that this “is an important point because we know that there is a certain tiredness in the population when it comes to receiving booster doses”.

Spain’s Minister of Health, Carolina Darias, previously predicted that the vaccine of the fourth dose against covid will begin in the second half of September.

Thank you for taking the time to read this article, do remember to come back and check The Euro Weekly News website for all your up-to-date local and international news stories and remember, you can also follow us on Facebook and Instagram.

Written by

Joshua Manning

Originally from the UK, Joshua is based on the Costa Blanca and is a web reporter for the Euro Weekly News covering international and Spanish national news. Got a news story you want to share? Then get in touch at


    • M

      02 August 2022 • 22:08

      Publish the safety trial data and details of a license to vaccinate, omicron only poses a problem for the old and vunerable as other coronaviruses (simple cold and flu viruses).
      forget the hype the healthly part of the population can deal with this milder form of Omicron.
      So in a nutshell if no transparancy of details are provided then one must assume there is other reasons behind this!

    Comments are closed.